Company
Makena
CVE:MKN
Makena is a junior exploration company dedicated to the aggressive pursuit of world class mineral deposits. Several upcoming project milestones make this an exciting time period for Makena’s corporate growth potential. Makena's Patterson Uranium Prospect consists of two claim blocks totaling 3,014 hectares (7,447 acres), which are located in the Athabasca Basin.
85 stories
Copper mining stock shines on takeover deal plus more daily small cap and micro cap movers
An all-stock takeover offer from Hudbay Minerals Inc powered shares of Copper Mountain Mining Corporation Thursday plus other big percentage movers on news from the small and micro cap space
Builders and building materials
Willow Biosciences stock climbs on business outlook plus more daily small cap movers
A bullish business outlook and financial guidance boosted shares of Willow Biosciences Inc Wednesday plus other big percentage movers on news from the small and micro cap space
Willow Biosciences to develop precision yeast fermentation for Kalsec to use in functional food and beverages
"We welcome the opportunity to advance Kalsec's range of natural, sustainable products while also evolving Willow's business strategy," said CEO Dr Peter Seufer-Wasserthal
Willow Biosciences sees operational platform make significant progress, confirms CEO appointment
"The third quarter saw us take another step forward in becoming a leader in precision fermentation," said the company's newly confirmed president and CEO, Dr Peter Seufer-Wasserthal
Willow Biosciences says work underway to commercially produce astaxanthin
"We are pleased to add astaxanthin as the next functional ingredient to our product portfolio,” said Willow CEO Dr Peter Seufer-Wasserthal
Willow Biosciences provides update on CBG, the first commercialized functional ingredient in its portfolio
"As we expand our portfolio of products and partnerships, we also remain committed to maximizing the value of our first functional ingredient, CBG, through continued development, operational improvements, and marketing efforts," said Willow
Willow Biosciences reports significant progress in 2Q, ends quarter in strong financial position
"The second quarter saw us take the next step in the evolution of our product portfolio with a new partnered pharmaceutical project," said Dr Peter Seufer-Wasserthal, interim president and CEO of Willow
Willow Biosciences appoints Dr Peter Seufer-Wasserthal as interim president and CEO, replacing Trevor Peters
The Vancouver-based company also said Willow director Barbara Munroe has been appointed as lead independent director
Willow Biosciences incorporates Inscripta’s digital genome engineering platform into its strain workflows
The move will enable Willow’s team to engineer strains more rapidly to give its researchers invaluable time to focus on intelligent library design and data analysis, the Vancouver-based company said
Willow Biosciences expands its portfolio with a new partnered pharmaceutical project
"This new partnership highlights the capabilities of our scientific team, and demonstrates to our stakeholders the wide array of opportunities accessible to Willow's comprehensive FutureGrown technology platform,” said Willow CEO Trevor Pet
Willow Biosciences says it is in position to capture value for shareholders in the coming biorevolution
Willow Biosciences CEO Trevor Peters said the company had a strong balance street and a world-class research and development team set up to capture value for shareholders
Willow Biosciences strikes manufacturing partnership to boost production capacity for its cannabinoid products
A new manufacturing services agreement with a contract development and manufacturing organization will help increase fermentation capacity to produce Willow’s FutureGrown platform
Willow Biosciences closes out 2021 with $30.1M in cash as it continues to progress its cannabinoid program
The company anticipates being able to add new compounds to its product offering in 2022 to generate revenue
Willow Biosciences announces first-ever peer reviewed study on clinical benefits of CBG for skincare
The results of the Willow study were published in Molecules, a leading international, peer-reviewed, open-access journal
Willow Biosciences poised to be the first company to commercially produce CBG, the "mother of all cannabinoids"
The Canadian company has developed a proprietary biosynthetic process to manufacture the cannabis compound in commercial quantities
Willow Biosciences closes 3Q with $35.7M in cash while making notable advancements in its operations
For the last three months of 2021, Willow plans to continue to optimize its commercial process for the rare cannabinoid CBG and build out a robust order book for 2022, which it expects to be its first full year of commercial production and
Willow Biosciences ramps up production titer; delivers corporate update
Earlier this year, the bio manufacturer completed its first commercial-scale fermentation run of cannabigerol (CBG) through its manufacturing partner’s European facilities
Willow Biosciences ends 2Q with C$40.7M in cash to support full commercialization of proprietary high-purity CBG in 2022
The company inked its first multiyear commercial agreement with cosmetics firm Cellular Goods to supply CBG for its skincare line
Willow Biosciences beefs up commercial and R&D teams as it expands portfolio to include additional cannabinoids
The firm has scaled up its lead program, cannabigerol, to start manufacturing the highly valuable and rare cannabinoid at a commercial level
NA Proactive news snapshot: Karora Resources, American Manganese, Idaho Champion Gold Mines Canada, MedX Health, Lingo Media UPDATE ...
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Willow Biosciences strikes first commercial supply agreement for CBG with UK cosmetics firm Cellular Goods
Cellular Goods will use Willow’s ultra-pure cannabigerol in its premium cannabinoid-based skincare products that are to be launched later in the year
Willow Biosciences added to NYSE-listed Cannabis ETF
It has been added to The Cannabis ETF, which contains 33 stocks that are expected to benefit from the growth of the legal global marijuana, cannabidiol and hemp industries
Willow Biosciences CEO Trevor Peters discusses how biosynthetically produced cannabinoids could shake up the cannabis industry
Willow's biosynthetic approach to creating THC, CBG and other plant-derived ingredients takes farming and plant-processing out of the picture, bringing benefits on environmental, cost and inventory management fronts
WIllow Biosciences ends 1Q with C$46.5M as it looks to its first CBG sales in 2Q
The Canadian biotechnology company further optimized its proprietary yeast strain to produce THC and completed its first commercial-scale fermentation run of CBG
Willow Biosciences reveals new clinical data showing the effectiveness of CBG on human skin
The company said studies have shown that Willow’s CBG is safe when applied to skin and eye areas, paving the way for its use in skincare
Willow Biosciences completes first commercial-scale fermentation run of ultra-pure CBG
Willow has already executed successful pilot production runs to optimize its process and provide samples of CBG to customers
Archive
NA Proactive news snapshot: WeedMD, Endeavour Mining, Newrange Gold, American Battery Metals, Power REIT UPDATE …
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Willow Biosciences on track to commercialize ultra-pure cannabinoids in 2021 with over C$47M in the bank
The company ended its 4Q 2020 with nearly C$16 million in cash on hand, a number that increased after a bought deal and warrant exercise in 1Q 2021
Willow Biosciences closes upsized bought deal offering for aggregate gross proceeds of approximately $28.75M after full exercise of over-allotment option
The company noted that participation in the Offering was comprised primarily of existing cornerstone shareholders and new institutional buyside funds
Willow Biosciences upsizes bought-deal financing raise to $25 million from initial $20.0 million
The net proceeds are expected to be used to help access new markets for its cannabinoid portfolio, expedite the commercialization of new cannabinoids, access additional manufacturing capacity, and working capital
Willow Biosciences is set to benefit from Jazz Pharmaceuticals acquisition of GW Pharmaceuticals
Willow Biosciences CEO Trevor Peters told Proactive the acquisition validates cannabinoids as having true pharmacological potential beyond treating childhood epilepsy
Willow Biosciences says it will be the first company to launch biosynthetically-produced THC in Canada
The Canadian company plans to commercialize the proprietary THC-producing yeast strain after it successfully launches its CBG-producing strain early this year
Willow Biosciences undertaking initiatives to help its customers evaluate and better understand CBG
CBG, or cannabigerol, is its first commercial cannabinoid that is slated for production in 1Q 2021
Willow Biosciences moves towards revenue generation as it expects first sales of CBG in second quarter of 2021
The biotech told investors it had selected a contract manufacturing organization to manufacture its first cannabinoid, cannabigerol (CBG)
Willow Biosciences ends 3Q with C$9.1M in cash after successful pilot production of CBG
CEO Trevor Peters said the quarter represented a “significant move forward” for the Calgary-based company ahead of commercial production anticipated to begin in 2021
Willow Biosciences CEO Trevor Peters is confident that the company will be the first to produce cannabigerol
The CEO shares exclusively with Proactive how the company plans to cross the finish line with commercial quantities of CBG
Willow Biosciences closes C$11.5M offering for cannabinoid commercialization
The company offered roughly 17.7 million units, each containing one share and one half a purchase warrant, at a price of C$0.65 per unit
Willow Biosciences boosts offering to $10 million due to excess demand
Willow has developed a proprietary process to produce high purity, plant-derived CBG and CBD compounds for the global pharmaceutical, health and wellness, and consumer packaged goods industries
Willow Biosciences partners with Lethbridge and Calgary universities to study the effects of non-psychoactive cannabinoids on intestinal inflammation, abdominal pain and depression
To support the research, Willow will be providing four different, non-plant derived cannabinoids for use in the study, which is set to begin in the 4Q of 2020
Willow Biosciences says it has successfully developed scalable process for producing CBG with greater than 99% purity and no detectable THC
The process was developed as part of a 500-litre pilot-scale campaign with partner Albany Molecular Research
Willow Biosciences set for Canada government funding to help advance its rare cannabinoids program
It will receive advisory services and conditional funding from the National Research Council of Canada Industrial Research Assistance Program
Willow Biosciences CEO says firm makes better-than-expected progress towards commercialization as it posts 2Q results
The company ended the quarter with strong liquidity, including around $12.2 million of cash on hand as of June 30, 2020, as it races towards production
ATB Capital says Willow Biosciences faces large commercialization opportunity with initial production run of CBG
Willow has developed a proprietary process to manufacture the cannabis compound in commercial quantities
Willow Biosciences kicks off pilot production run of high-purity CBG, a non-psychoactive cannabinoid compound
Willow will manufacture the high purity, plant-derived compounds for pharmaceutical, health and wellness and consumer packaged goods industries